| Nicole Kay Summerson, OTR/L | |
|
7251 W 20th St Bldg P2, Greeley, CO 80634-4625 | |
| (970) 702-2507 | |
| Not Available |
| Full Name | Nicole Kay Summerson |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 6 Years |
| Location | 7251 W 20th St Bldg P2, Greeley, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346716222 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT.0005688 (Colorado) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Noco Pediatric Ot Llc | 8820404809 | 4 |
News Archive
Despite significant advances in kidney care over the past 20 years, efforts to improve therapy for type 1 diabetes patients with kidney dysfunction remain unsuccessful, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that more effective therapies are needed for these patients.
As 2017 comes to a close, many states have enacted laws and regulations expanding access to healthcare provided by advanced practice registered nurses, according to the 30th Annual Legislative Update in the January issue of The Nurse Practitioner, published by Wolters Kluwer.
After Nelson Mandela was released from prison February 11, 1990, all children born in the great Johannesburg area were enrolled in a 20-year longitudinal study. Officially known as "Birth to Twenty," the study and its 3,273 youth, are colloquially referred to as "Mandela's Children." It's the largest and longest running study of child and adolescent health and development in Africa, and one of the few large-scale longitudinal studies in the world.
A drug used to treat erectile dysfunction may prevent functional muscle ischemia in patients with Becker muscular dystrophy, a small randomized trial shows.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
| Provider Name | Noco Pediatric Ot Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1750726386 PECOS PAC ID: 8820404809 Enrollment ID: O20210317002105 |
News Archive
Despite significant advances in kidney care over the past 20 years, efforts to improve therapy for type 1 diabetes patients with kidney dysfunction remain unsuccessful, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that more effective therapies are needed for these patients.
As 2017 comes to a close, many states have enacted laws and regulations expanding access to healthcare provided by advanced practice registered nurses, according to the 30th Annual Legislative Update in the January issue of The Nurse Practitioner, published by Wolters Kluwer.
After Nelson Mandela was released from prison February 11, 1990, all children born in the great Johannesburg area were enrolled in a 20-year longitudinal study. Officially known as "Birth to Twenty," the study and its 3,273 youth, are colloquially referred to as "Mandela's Children." It's the largest and longest running study of child and adolescent health and development in Africa, and one of the few large-scale longitudinal studies in the world.
A drug used to treat erectile dysfunction may prevent functional muscle ischemia in patients with Becker muscular dystrophy, a small randomized trial shows.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Kay Summerson, OTR/L 4650 Royal Vista Cir, Windsor, CO 80528-9321 Ph: () - | Nicole Kay Summerson, OTR/L 7251 W 20th St Bldg P2, Greeley, CO 80634-4625 Ph: (970) 702-2507 |
News Archive
Despite significant advances in kidney care over the past 20 years, efforts to improve therapy for type 1 diabetes patients with kidney dysfunction remain unsuccessful, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that more effective therapies are needed for these patients.
As 2017 comes to a close, many states have enacted laws and regulations expanding access to healthcare provided by advanced practice registered nurses, according to the 30th Annual Legislative Update in the January issue of The Nurse Practitioner, published by Wolters Kluwer.
After Nelson Mandela was released from prison February 11, 1990, all children born in the great Johannesburg area were enrolled in a 20-year longitudinal study. Officially known as "Birth to Twenty," the study and its 3,273 youth, are colloquially referred to as "Mandela's Children." It's the largest and longest running study of child and adolescent health and development in Africa, and one of the few large-scale longitudinal studies in the world.
A drug used to treat erectile dysfunction may prevent functional muscle ischemia in patients with Becker muscular dystrophy, a small randomized trial shows.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
Troy Ridgeway, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1025 9th Ave, Greeley, CO 80631 Phone: 970-348-6000 | |
Erin Coram, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1025 9th Ave, Greeley, CO 80631 Phone: 970-348-6000 | |
Avery June Pulley, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1931 65th Ave Ste C, Greeley, CO 80634 Phone: 970-305-5070 | |
Noco Pediatric Ot, Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1931 65th Ave Ste C, Greeley, CO 80634 Phone: 970-305-5070 Fax: 970-541-0357 | |
Lauren Brooks, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1025 9th Ave, Greeley, CO 80631 Phone: 970-348-6103 | |
Alanna Kelly Lowe, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5699 W 20th St, Greeley, CO 80634 Phone: 970-451-1234 | |
Mrs. Dawn Michelle Conley, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1700 18th Ave, Greeley, CO 80631 Phone: 970-313-1515 Fax: 970-346-1834 |